<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prevention of sexually transmitted infections</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prevention of sexually transmitted infections</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prevention of sexually transmitted infections</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kees Rietmeijer, MD, PhD, MSPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeanne Marrazzo, MD, MPH, FACP, FIDSA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 22, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sexually transmitted infections (STIs) are common and preventable causes of morbidity and serious complications. Untreated chlamydial and gonococcal infection may result in pelvic inflammatory disease, which can lead to infertility, ectopic pregnancy, and chronic pelvic pain in 10 to 20 percent of cases [<a href="#rid1">1</a>]. STIs can also result in adverse outcomes in pregnancy, including spontaneous abortion, still birth, premature birth, and congenital infection [<a href="#rid2">2</a>]. Finally, the presence of STIs can facilitate HIV transmission [<a href="#rid3">3-5</a>]. Thus, primary prevention of STIs needs to be given high priority.</p><p>The comprehensive approach to STI prevention is based on six major strategies [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Accurate sexual health assessment (including sexual orientation and gender identification), with education and counseling on ways to avoid STIs</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pre-exposure vaccination for vaccine-preventable STIs</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identification of both asymptomatic and symptomatic individuals with STIs</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Effective diagnosis, treatment, counseling, and follow-up of infected individuals</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation, treatment, and counseling of sex partners of infected individuals</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antimicrobial pre- or post-exposure prophylaxis (PrEP/PEP) against certain STIs </p><p></p><p>This topic addresses sexual health assessment, counseling, vaccination, and antimicrobial-based preventive strategies. </p><p>Screening for STIs is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7596.html" rel="external">"Screening for sexually transmitted infections"</a>.)</p><p>Diagnosis, treatment, and follow-up of individual STIs are discussed in the specific topic reviews. Prevention of HIV infection is also discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/16612.html" rel="external">"HIV infection: Risk factors and prevention strategies"</a>.) </p><p>Prevention of sexual transmission of Zika virus is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/106169.html" rel="external">"Zika virus infection: An overview", section on 'Sexual transmission'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">SEXUAL HEALTH ASSESSMENT</span></p><p class="headingAnchor" id="H315313356"><span class="h2">Approach</span><span class="headingEndMark"> — </span>An assessment of sexual health and behavior is critical to appropriately targeting individuals for STI screening  (<a class="graphic graphic_table graphicRef103391" href="/d/graphic/103391.html" rel="external">table 1</a>) and prevention counseling. At a minimum, a sexual health assessment should include questions regarding the patient's sexual orientation and gender identification as a lead-in to more specific questions that will assess the need for further STI evaluation, testing, and treatment. The "Five P's" approach is a framework to further assess an individual's sexual health by systematically and non-judgmentally asking about partners, prevention of pregnancy, protection against STI, sexual practices, and past history of STI  (<a class="graphic graphic_table graphicRef61677" href="/d/graphic/61677.html" rel="external">table 2</a>). In addition, a comprehensive sexual history should also include other aspects of sexual health, including positive (enjoyment) and negative (pain, coercion) features. Assessment of any history of substance use, which may be associated with increased risk for STI, is also important. </p><p>Rather than focusing on the risks for STIs, we favor framing the approach to STI prevention as a more positive sexual health approach that acknowledges the acquisition of STIs in the context of otherwise normal sexual behaviors [<a href="#rid7">7</a>]. A risk-based approach has limitations. It tends to perpetuate the stigma surrounding STIs, which can deter individuals disproportionally affected by STIs from seeking care and prevention services [<a href="#rid8">8</a>]. In addition, a risk-based approach is not particularly helpful for persons who perceive themselves to be in monogamous relationships or otherwise at low risk. Furthermore, certain sexual behaviors may not be associated with an increased risk for all STIs (eg, with the use of pre-exposure prophylaxis, the risk of HIV with condomless sex is substantially decreased but the risk of other STIs is unaffected) [<a href="#rid9">9</a>]. </p><p>Shifting to a sexual health paradigm can promote a change in the discourse on STI prevention that should inform sexual education in families, schools, faith-based institutions, and other societal platforms. Additionally, "normalization" of sexual behavior may facilitate STI prevention in the health care setting. These considerations are in alignment with the 2021 published report by the National Academies of Sciences, Engineering, and Medicine: “Sexually Transmitted Infections – Adopting a Sexual Health Paradigm” [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H1174843170"><span class="h2">Factors associated with STI acquisition</span><span class="headingEndMark"> — </span>A comprehensive sexual assessment should be able to identify behavioral factors that increase the risk of STI acquisition. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>New sex partner in past 60 days</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Condomless vaginal, anal, or oral sex with multiple sex partners or with a sex partner with multiple concurrent sex partners</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sex with partners recently treated for an STI</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Trading sex for money or drugs</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sexual contact (oral, anal, penile, or vaginal) with sex workers</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Disproportionately affected populations</span><span class="headingEndMark"> — </span>Some individuals warrant specific considerations for STI screening and counseling because they belong to particular groups associated with a high prevalence of STIs. (See  <a class="medical medical_review" href="/d/html/7596.html" rel="external">"Screening for sexually transmitted infections"</a>.) </p><p class="headingAnchor" id="H596598953"><span class="h3">Adolescents</span><span class="headingEndMark"> — </span>Health care providers should routinely ask adolescents about sexual activity and should offer screening for STIs and counseling on prevention to sexually active adolescents [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/7596.html" rel="external">"Screening for sexually transmitted infections", section on 'Screening recommendations'</a> and  <a class="medical medical_review" href="/d/html/115.html" rel="external">"Sexually transmitted infections: Issues specific to adolescents", section on 'Evaluation for STIs'</a>.)</p><p>In the United States, approximately one-half of the estimated 19 million incident STIs each year occur in young people aged 15 to 24 years [<a href="#rid11">11</a>]. The United States Centers for Disease Control and Prevention (CDC) created the Youth Risk Behavioral Surveillance System, a school-based periodic survey to monitor health behaviors associated with morbidity, including STIs, among adolescents. In 2019, 38.4 percent of high school students had any history of sexual intercourse (down from 41 percent in 2015 and 54 percent in 1991), and 8.6 percent reported four or more lifetime sexual partners (down from 12 percent in 2015 and 19 percent in 1991) [<a href="#rid12">12</a>]. These favorable trends are partly offset by the decreased proportion of sexually active students reporting condom use at last sexual intercourse, from 63 to 57 percent between 2003 and 2015, to 54 percent in 2017 and 2019, after having increased from 46 percent in 1991 [<a href="#rid12">12-14</a>]. </p><p class="headingAnchor" id="H1778827202"><span class="h3">Men who have sex with men</span><span class="headingEndMark"> — </span>A careful sexual health assessment, as outlined above, should be conducted for all male patients regardless of sexual orientation, and prevention counseling should be offered accordingly [<a href="#rid15">15,16</a>]. Clinicians should also routinely ask patients about symptoms consistent with common STIs, including urethral discharge, dysuria, ulcers, or anorectal symptoms. Men who have sex with men (MSM) warrant particular consideration in the approach to STI prevention. (See  <a class="medical medical_review" href="/d/html/7596.html" rel="external">"Screening for sexually transmitted infections", section on 'Assessing risk'</a>.)</p><p>Despite significant advances in the prevention of HIV transmission, particularly through the use of antiretroviral medications, MSM are still disproportionally affected by the HIV epidemic. </p><p>In addition, increased rates of syphilis, gonorrhea, and chlamydial infections have been reported in many cities in the United States and Europe and disproportionately affect MSM with HIV. The resurgence of STIs, particularly gonorrhea and syphilis, among MSM has been documented since the late 1990s and has been linked to the availability of effective antiretroviral therapy (ART), which has reduced the fear of AIDS [<a href="#rid9">9</a>]. MSM also have a higher than typical risk of sexual exposure to viral hepatitis. (See  <a class="medical medical_review" href="/d/html/7600.html" rel="external">"Syphilis in patients with HIV"</a> and  <a class="medical medical_review" href="/d/html/7584.html" rel="external">"Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/d/html/7587.html" rel="external">"Epidemiology and pathogenesis of <i>Neisseria gonorrhoeae</i> infection", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/d/html/89490.html" rel="external">"Epidemiology of <i>Chlamydia trachomatis</i> infections"</a>.) </p><p>More recently, MSM receiving pre-exposure prophylaxis (PrEP) to prevent HIV acquisition have been shown to have a higher prevalence of other STIs. As an example, in a study of over 650 individuals initiating PrEP in San Francisco, California, no new HIV infections were identified, but over 40 percent reduced the use of condoms, and 50 percent had an incident STI within 12 months [<a href="#rid17">17</a>]. The success of ART-based HIV prevention has effectively uncoupled epidemiologic synergy between HIV and other STIs and has led to a "new normal," in which HIV prevention and STI prevention have become unlinked [<a href="#rid9">9</a>]. Thus, routine screening for bacterial STIs is an emerging standard of care for patients living with HIV and persons using PrEP. (See  <a class="medical medical_review" href="/d/html/113426.html" rel="external">"HIV pre-exposure prophylaxis", section on 'Patient monitoring'</a>.)</p><p>In addition, outbreaks of infections that have not traditionally been classified as STIs have occurred in MSM populations, among whom close and sexual contact has been identified as major routes of transmission. These include: </p><p class="bulletIndent1"><span class="glyph">●</span>Invasive meningococcal disease – Sporadic outbreaks have been detected among MSM in several cities in the United States and Europe since 2010. These are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1298.html" rel="external">"Epidemiology of Neisseria meningitidis infection", section on 'Men who have sex with men'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mpox (formerly referred to as monkeypox) virus infection – In 2022, a rapidly expanding outbreak involved thousands of cases in numerous countries and regions beyond the endemic regions of Central and West Africa, including the United States and Europe [<a href="#rid17">17-19</a>]. MSM were disproportionately affected in this outbreak, which had largely subsided by late 2022. Epidemiology of the 2022 mpox outbreak, the clinical features and diagnosis, management, and prevention of mpox are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/139254.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of mpox (monkeypox)"</a> and  <a class="medical medical_review" href="/d/html/8295.html" rel="external">"Treatment and prevention of mpox (monkeypox)"</a>.)</p><p></p><p>Given that sexual exposure is a predominant mode of transmission in outbreaks of these infections among MSM, preventive measures outlined in this topic apply to prevention of these infections as well as to traditional STIs.</p><p class="headingAnchor" id="H3336088751"><span class="h3">Transgender and non-binary individuals</span><span class="headingEndMark"> — </span>Transgender individuals identify with a gender that is opposite from their sex at birth. Non-binary persons do not identify with either sex or identify somewhere on a spectrum between the sexes. Gender identity is distinct from sexual orientation, and factors associated with STI acquisition vary widely in this population. Overall, transgender/non-binary individuals have a higher prevalence of sexually transmitted and nonsexually transmitted HIV infection and STIs than the general population [<a href="#rid20">20</a>]. STI screening and counseling in this population should be tailored to the individual's anatomy and sexual behavior. (See  <a class="medical medical_review" href="/d/html/7596.html" rel="external">"Screening for sexually transmitted infections", section on 'Transgender and gender-diverse persons'</a>.)</p><p class="headingAnchor" id="H3280264"><span class="h3">People with HIV</span><span class="headingEndMark"> — </span>High rates of STIs have been identified through screening programs among people with HIV worldwide. Routine STI screening and counseling of people with HIV are recommended in order to reduce the spread of STIs, particularly because some STIs, in turn, can increase HIV transmission. (See  <a class="medical medical_review" href="/d/html/7596.html" rel="external">"Screening for sexually transmitted infections", section on 'Patients with HIV infection'</a>.)</p><p class="headingAnchor" id="H3077297818"><span class="h3">Pregnant individuals</span><span class="headingEndMark"> — </span>Because of the potential for high morbidity among pregnant individuals with STIs and poor fetal outcomes following maternal infection, all pregnant patients should be screened for STIs at the first prenatal visit [<a href="#rid6">6</a>]. In the United States, the resurgence of congenital syphilis underscores the importance of this recommendation [<a href="#rid21">21</a>]. Individuals disproportionally exposed to STIs, including those with new and/or potentially untreated partners and those living in communities with high STI prevalence, should be screened more often during pregnancy. Details on screening pregnant individuals are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/83303.html" rel="external">"Prenatal care: Second and third trimesters", section on 'Screen for sexually transmitted infections'</a> and  <a class="medical medical_review" href="/d/html/446.html" rel="external">"Prenatal care: Initial assessment", section on 'Infection'</a>.) </p><p>Prevention of sexual transmission of Zika virus among pregnant patients is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/107211.html" rel="external">"Zika virus infection: Evaluation and management of pregnant patients", section on 'Prevention'</a>.)</p><p class="headingAnchor" id="H331723268"><span class="h1">SCREENING</span><span class="headingEndMark"> — </span>The identification and treatment of persons with STIs and their partners are a key strategy in the prevention of STIs  (<a class="graphic graphic_table graphicRef103391" href="/d/graphic/103391.html" rel="external">table 1</a>). STI screening is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7596.html" rel="external">"Screening for sexually transmitted infections"</a>.)</p><p class="headingAnchor" id="H908275850"><span class="h1">PREVENTION COUNSELING</span></p><p class="headingAnchor" id="H567085640"><span class="h2">Populations to counsel</span><span class="headingEndMark"> — </span>Interventions focused on behavioral modification are a major element of the public health approach to STI risk reduction and control. The United States Preventive Services Task Force recommends behavioral counseling interventions to prevent STIs for all sexually active adolescents and for adults who are disproportionately affected by STIs because they can reduce STI rates and reduce behavior associated with STI exposure [<a href="#rid22">22</a>]. (See <a class="local">'Disproportionately affected populations'</a> above.)</p><p>The United States Centers for Disease Control and Prevention (CDC) also emphasizes the importance of prevention counseling for all sexually active adolescents and for all adults who have received an STI diagnosis, have had an STI in the past year, or have multiple partners [<a href="#rid6">6</a>]. </p><p class="headingAnchor" id="H2812272273"><span class="h2">Content of counseling</span><span class="headingEndMark"> — </span>Behavioral interventions should be offered to provide information on STI transmission, educate about behaviors that can increase exposure to STIs, and aim to increase motivation to adjust behavior to reduce STI exposure. Specific sexual practices that are important to highlight include condomless anal sex and sex with multiple partners, potentially amplified by concomitant use of alcohol or drugs [<a href="#rid23">23</a>]. Proper condom use should be reviewed, and women should be counseled that contraceptive methods that are not mechanical barriers offer no protection against HIV or other STIs. (See <a class="local">'Male condom use'</a> below.)</p><p>Patient-centered counseling that involves a discussion tailored to the individual situation can be performed during a single, brief clinic session [<a href="#rid6">6</a>]. One useful framework for patient-centered counseling is the "Ask, Screen, Intervene" curriculum, developed by the National Network of STD/HIV Prevention Training Center in partnership with the AIDS Education and Training Centers [<a href="#rid24">24</a>]. Within this framework, following an assessment of the patient's sexual health and indications for screening (see <a class="local">'Sexual health assessment'</a> above and  <a class="medical medical_review" href="/d/html/7596.html" rel="external">"Screening for sexually transmitted infections"</a>), elements of brief behavioral counseling for risk reduction include:</p><p class="bulletIndent1"><span class="glyph">●</span>Discussing how various sexual behaviors can expose a person to STIs</p><p class="bulletIndent1"><span class="glyph">●</span>Assessing the patient's understanding and beliefs about STI transmission</p><p class="bulletIndent1"><span class="glyph">●</span>Assessing the circumstances that affect the patient's sexual behavior</p><p class="bulletIndent1"><span class="glyph">●</span>Assessing the patient's readiness to change</p><p class="bulletIndent1"><span class="glyph">●</span>Negotiating a behavioral goal</p><p class="bulletIndent1"><span class="glyph">●</span>Identifying a concrete and realistic first step toward the goal</p><p></p><p>Additional details and example questions are found in the table  (<a class="graphic graphic_table graphicRef111349" href="/d/graphic/111349.html" rel="external">table 3</a>). Providers can also use motivational interviewing techniques to move clients toward achievable behavioral goals. (See  <a class="medical medical_review" href="/d/html/14612.html" rel="external">"Overview of psychotherapies", section on 'Motivational interviewing'</a> and  <a class="medical medical_review" href="/d/html/16752.html" rel="external">"Substance use disorders: Motivational interviewing"</a>.)</p><p class="headingAnchor" id="H1515656829"><span class="h2">Setting</span><span class="headingEndMark"> — </span>Behavioral interventions can be administered in any outpatient setting and include in-person counseling, telephone support, and other media-delivered messages (videos, websites, text messaging, written material). Although interventions characterized by multiple sessions over a short period in a peer-group setting appear to be associated with the greatest reductions in STIs, they are resource intensive; briefer, single-session interventions can also be effective and may be more practical. Given the lack of continuity of care in the STI clinical environment, CDC recommendations emphasize the possible utility of brief, single-session counseling sessions [<a href="#rid25">25</a>]. In such settings, other low-intensity interventions, such as waiting room videos, can also be useful counseling strategies. Resources and training documents on behavioral intervention strategies can be found at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fstd%2Fproducts%2Fdefault.htm&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLCJCihS2PqegOXkuiePwOHOEw6wDyf0pZNgIvFC5d0ow5%2BgbOtyy57EMnNTW09E4Zg%3D%3D&amp;TOPIC_ID=7595" target="_blank">CDC sexually transmitted infection website</a>.</p><p class="headingAnchor" id="H3152855763"><span class="h2">Efficacy</span><span class="headingEndMark"> — </span>A 2020 systematic review identified 37 randomized and 2 nonrandomized trials evaluating the efficacy of a variety of behavioral interventions [<a href="#rid26">26</a>]. The review noted with moderate certainty evidence that these interventions reduce the risk of STI in sexually active adolescents and adults disproportionately affected by STIs. In a meta-analysis of 19 of those trials, behavioral interventions were associated with a reduction in STI incidence over the follow-up time, most commonly 6 to 12 months (pooled odds ratio 0.66, 95% CI 0.54-0.81), although there was substantial statistical and clinical heterogeneity. Larger effect sizes were observed in studies that evaluated adolescents, high-intensity interventions (ie, &gt;2 hours), or group counseling. Other outcomes highlighted in the systematic review included higher odds of condom use, lower rates of condomless sexual encounters, and fewer sexual partners with behavioral interventions. </p><p>Although most studies have evaluated high-intensity behavioral interventions, certain low-intensity behavioral interventions can also be effective, especially if large groups of persons can be exposed to a simple intervention. As an example, a controlled study following over 40,000 patients in three United States STI clinics demonstrated an almost 10 percent reduction in incident STIs among those exposed to a waiting room condom promotion video ("Safe in the City") [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H6"><span class="h1">VACCINES</span><span class="headingEndMark"> — </span>Vaccinations are available for the prevention of several infections that are sexually transmitted or associated with sexual activity; these include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8519" href="/d/drug information/8519.html" rel="external">Hepatitis A vaccine</a> (see  <a class="medical medical_review" href="/d/html/3900.html" rel="external">"Hepatitis A virus infection: Treatment and prevention", section on 'Vaccination'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatitis B vaccine (see  <a class="medical medical_review" href="/d/html/3641.html" rel="external">"Hepatitis B virus immunization in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Human papillomavirus (HPV) (see  <a class="medical medical_review" href="/d/html/8325.html" rel="external">"Human papillomavirus vaccination"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>N. meningitidis </em>(see  <a class="medical medical_review" href="/d/html/3901.html" rel="external">"Meningococcal vaccination in children and adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mpox (formerly known as monkeypox) virus (see  <a class="medical medical_review" href="/d/html/8295.html" rel="external">"Treatment and prevention of mpox (monkeypox)", section on 'Orthopoxvirus vaccines'</a>)</p><p></p><p>However, effective vaccines are not available for a number of traditional STIs, including chlamydia, gonorrhea, syphilis, and HIV. </p><p>Nevertheless, growing evidence suggests that outer membrane vesicle meningitis B vaccines (eg, MenB-4C) provide some protection against gonorrhea. In a randomized trial presented in abstract form only that included over 500 men who have sex with men (MSM), receipt of MenB-4C reduced the risk of gonorrhea (10 versus 20 cases per person year, adjusted hazard ratio [HR] 0.49, 95% CI 0.27-0.88) [<a href="#rid28">28</a>]. Observational studies have also demonstrated an association between outer membrane vesicle meningitis B vaccination and decreased gonorrhea rates [<a href="#rid29">29-32</a>]. The observed protection may be related to homology of the outer membrane vesicle proteins among <em>N. gonorrhoeae </em>and <em>N. meningitidis</em>. An effective vaccine for <em>N. gonorrhoeae</em> has been elusive, in part because infection does not confer immunity to future reinfection, which is likely related to antigenic variability of its surface proteins. Additional evaluation of outer membrane vesicle meningitis B vaccines for prevention of gonorrhea, including the potential for long-term protection, is warranted before their use can be routinely recommended for this purpose.</p><p class="headingAnchor" id="H11"><span class="h1">MALE CONDOM USE</span><span class="headingEndMark"> — </span>Condom use is one of the most effective means of preventing STIs [<a href="#rid33">33</a>]. Both the United States Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) assert the protective value of condoms in preventing STIs, and the WHO has incorporated condoms as an essential component in public health strategies to prevent STIs [<a href="#rid6">6,34</a>]. The amount of protection provided by condom use for the prevention of HIV and other STIs is difficult to establish given the ethical limitations of conducting randomized controlled trials. (See <a class="local">'Efficacy'</a> below.)</p><p class="headingAnchor" id="H1014044209"><span class="h2">Instructions on use</span><span class="headingEndMark"> — </span>Patients should be advised that condoms must be used consistently and correctly to be effective in preventing STIs [<a href="#rid6">6</a>]. </p><p>Latex condoms are the type most commonly used in studies of STI prevention (see <a class="local">'Efficacy'</a> below). Polyurethane male condoms likely provide similar protection. Condoms made of other synthetic material and "natural membrane" condoms (sometimes referred to as "lambskin") should not be used for STI prevention, as they are too porous to prevent transmission of common pathogens, especially viruses. </p><p>Latex condoms should not be used five years after the manufacturing date or past the expiration date. A new condom should be used for each sex act, and it should be handled carefully to avoid tears or damage. The condom should be placed on after the penis is erect and prior to genital, oral, or anal contact with the partner. </p><p>Adequate lubrication with vaginal and anal sex should be ensured, but if exogenous lubrication is needed, only water-based lubricants should be used with latex condoms since oil-based lubricants (petroleum jelly, <a class="drug drug_general" data-topicid="10213" href="/d/drug information/10213.html" rel="external">mineral oil</a>) can weaken latex. Either water- or oil-based lubricants can be used with polyurethane condoms. </p><p>To prevent slippage, the penis should be withdrawn while erect and the condom should be held firmly against the base of the penis during withdrawal. </p><p>Condoms are regulated as medical devices. In the United States, each latex condom manufactured is tested electronically for holes before packaging. Failure of condoms usually results from inconsistent or incorrect use rather than condom breakage [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H3375720990"><span class="h2">Efficacy</span><span class="headingEndMark"> — </span>Overall, evidence supports the efficacy of condoms in preventing most STIs. Studies on the efficacy of condom use are subject to a number of limitations [<a href="#rid35">35</a>]. Assessment of condom use is generally by self-report, which may be unreliable. Incorrect use of condoms that would reduce their efficacy is rarely evaluated, and frequency of condom use is usually recorded as a static measure, when it may change over time. Each of these factors would underestimate the efficacy of appropriate condom use. </p><p>Nevertheless, in 2000, an expert panel convened by the National Institutes of Health performed a critical review of available scientific literature on the efficacy of condoms and concluded that condom use prevented HIV transmission in both men and women during vaginal intercourse and prevented gonorrhea in men [<a href="#rid36">36</a>]. It noted that there were insufficient data to draw conclusions on the ability of condoms to prevent other STIs [<a href="#rid36">36</a>]. However, since this publication, multiple other prospective studies have been reported that have contributed substantially to understanding the protective role of condoms in other STIs, including chlamydia, gonorrhea, herpes simplex type 2, trichomoniasis, and human papillomavirus [<a href="#rid37">37</a>]. </p><p>The following discusses condom efficacy by specific STI:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>HIV</strong> – HIV can be transmitted through anal, penile-vaginal, and oral intercourse, but the far greatest risk is with anal intercourse. Consistent and proper use of condoms is estimated to prevent HIV transmission by approximately 80 to 95 percent [<a href="#rid38">38-40</a>]. (See  <a class="medical medical_review" href="/d/html/16612.html" rel="external">"HIV infection: Risk factors and prevention strategies", section on 'Condom use'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gonorrhea, chlamydia, and </strong><strong><em>Trichomonas</em></strong><em> </em>– These organisms cause the majority of nonviral STIs worldwide. Precise transmission rates of these organisms are unknown but thought to be high [<a href="#rid36">36</a>]. Data on gonorrhea suggest an average transmission of one infection for every two exposures. Gonorrhea and chlamydia are more efficiently transmitted from males to females; male to female transmission of <em>N. gonorrhoeae</em> is approximately fourfold more efficient than female to male. A systematic review of studies published from 1966 to 2004 evaluated the effectiveness of condom use in preventing gonorrhea and chlamydia; most studies reviewed demonstrated a reduced risk of infection [<a href="#rid41">41</a>]. As an example, in a prospective study of adolescent African-American females, self-reported 100 percent condom use was associated with a lower incidence of gonorrhea, chlamydia, or trichomoniasis (18 versus 30 percent among those who did not use condoms consistently) [<a href="#rid42">42</a>]. Similarly, studies among female sex workers have shown associations between condom use promotion and decreased risk of gonorrhea, chlamydia, and <em>Trichomonas </em>infections [<a href="#rid37">37,43,44</a>].</p><p></p><p class="bulletIndent1">Additionally, among women with a history of pelvic inflammatory disease (PID), consistent use of condoms has been associated with lower rates of recurrent PID, chronic pelvic pain, and infertility [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genital herpes</strong> – Transmission of herpes simplex viruses (HSV) type 1 and type 2 can occur during symptomatic and asymptomatic periods due to intermittent viral shedding. Consistent condom use has been demonstrated to decrease the risk of HSV-2 transmission to an uninfected partner by up to 96 percent, although this appears more effective in preventing transmission from men to women than vice versa [<a href="#rid46">46-48</a>]. (See  <a class="medical medical_review" href="/d/html/8344.html" rel="external">"Prevention of genital herpes virus infections", section on 'Condom use'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Human papillomavirus</strong> – Condom use has been associated with a reduction in the risk of acquiring human papillomavirus (HPV) infection, clearance of infection, and higher rates of regression of cervical intraepithelial neoplasia in women and penile lesions in men [<a href="#rid49">49-55</a>]. As an example, in a study of 82 females who reported no prior sexual encounters, consistent condom use was associated with a 70 percent lower risk of incident HPV infection compared with condom use &lt;5 percent of the time [<a href="#rid49">49</a>]. Condom use was also effective in preventing cervical intraepithelial lesions. In a separate study of over 3000 men who have sex with women and had no baseline HPV infection, self-reported consistent condom use was associated with a decreased 12-month incidence of anogenital HPV infection among those with no steady sexual partner (hazard ratio 0.54, 95% CI 0.3-0.95, compared with no condom use) [<a href="#rid54">54</a>]. There was no detected association between condom use and HPV infection among men who had a steady sexual partner, regardless of whether they were monogamous or nonmonogamous.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Syphilis </strong>– <em>Treponema pallidum</em> is transmitted by direct contact with syphilitic sores, which may be present on the external genitalia, vagina, anus, rectum, lips, and mouth; only a few organisms are required to infect a person through abraded skin. The primary chancre is often painless but teeming with spirochetes. A systematic review of condom use and risk of STIs determined that only two studies were rigorously designed to longitudinally assess the effects on incident syphilis; one study suggested a significantly reduced risk of syphilis among condom users [<a href="#rid56">56</a>].</p><p></p><p class="headingAnchor" id="H23"><span class="h2">Potential risk of spermicides</span><span class="headingEndMark"> — </span>Condoms lubricated with spermicides are no more effective than other lubricated condoms in protecting against the transmission of HIV and other STIs. Studies of spermicides containing <a class="drug drug_general" data-topicid="10170" href="/d/drug information/10170.html" rel="external">nonoxynol-9</a> (N-9) have produced conflicting results on the ability to prevent STIs other than HIV [<a href="#rid57">57,58</a>]. However, two randomized controlled trials reported an increased risk of HIV acquisition with frequent use of N-9, possibly due to disruption of the genital epithelium [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H206690279"><span class="h2">Other barrier methods</span><span class="headingEndMark"> — </span>Most data on the efficacy of condoms are related to male condom use rather than female condom use [<a href="#rid36">36</a>]. In several randomized controlled trials, male condoms have been superior to other barrier methods in preventing new STIs, and other studies have reported very low uptake of the female condom [<a href="#rid58">58</a>]. The data on the protective effect of cervical diaphragms are mixed, and these should not be relied upon for STI prevention [<a href="#rid6">6</a>]. Use of a latex diaphragm with lubricant gel in addition to condoms had no additive effect on preventing HIV, chlamydia, or gonorrhea [<a href="#rid59">59,60</a>].</p><p class="headingAnchor" id="H3280414"><span class="h1">ANTIMICROBIAL-BASED PREVENTION STRATEGIES</span></p><p class="headingAnchor" id="H2143382765"><span class="h2">Doxycycline post-exposure prophylaxis for selected individuals</span><span class="headingEndMark"> — </span>Among individuals disproportionally affected by STIs, including men who have sex with men (MSM), post-exposure prophylaxis (PEP) with <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> appears to reduce the incidence of certain bacterial STIs. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Deciding whether to use </strong><strong>doxycycline</strong><strong> PEP</strong> – In the United States, the Centers for Disease Control and Prevention (CDC) has not yet published recommendations on <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> PEP; for clinicians who are considering it for certain patients, the CDC emphasizes that supportive efficacy data are only available for MSM and transgender women and that antibiotics other than doxycycline should not be used [<a href="#rid61">61</a>]. Pending more definitive guidance, some STI clinics have developed <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.sfcdcp.org%2Fwp-content%2Fuploads%2F2022%2F10%2FHealth-Update-Doxycycline-Post-Exposure-Prophylaxis-Reduces-Incidence-of-Sexually-Transmitted-Infections-SFDPH-FINAL-10.20.2022.pdf&amp;token=heMZ04%2BKT1mRGYM%2FTMF2k9jElmHVPsyMnoaZxiyhCBIZsBVjV5pxl3%2BAZ4l3tuJ1iDdKY7jiNT961iUhz5tIPug%2BZWcHMFd%2BQvPBeu%2FsnP45QxV%2Bllnye%2B6C0GTL%2F3ur3X%2Fe0%2FcOTvLvnJKEAVF%2F3PT2ZjOftF0CSB4Ex%2FKEKXJVZEaZQiQ3QIZYgmA3yK%2BJPpNu%2FoyLuNmGd0J3R%2BZ%2BDw%3D%3D&amp;TOPIC_ID=7595" target="_blank">protocols</a> for the delivery of doxycycline PEP and offer it on a case-by-case basis [<a href="#rid62">62</a>]. Similarly, we individualize the decision to use doxycycline PEP given uncertainties around the long-term effect.</p><p></p><p class="bulletIndent1">If <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> PEP is used, doxycycline 200 mg is taken once orally within 72 hours of condomless sex, with a maximum dose of 200 mg each day. Individuals receiving doxycycline PEP also warrant frequent (eg, every three to six months) screening for STIs  (<a class="graphic graphic_table graphicRef103391" href="/d/graphic/103391.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Data suggest that among MSM and transgender women, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> PEP can reduce the risk of chlamydia, syphilis, and, in some studies, gonorrhea [<a href="#rid28">28,63-65</a>]. However, studies have failed to demonstrate efficacy among cisgender women. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In an open-label randomized trial from France that included approximately 200 MSM who were already enrolled in a trial of pre-exposure prophylaxis for HIV (PrEP), <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> for STI PEP, administered as two 100 mg pills within 72 hours of a condomless sexual exposure, reduced the incidence of chlamydia (hazard ratio [HR] 0.30, 95% CI 0.13-0.70) and syphilis (HR 0.27 95% CI 0.07–0.98) over a median of nine months follow-up [<a href="#rid64">64</a>]. There was no effect on gonorrhea rates, likely because of the prevalence of <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> resistance among <em>N. gonorrhoeae</em>. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Similarly, in a randomized trial that included 327 MSM and transgender women in San Francisco who were on PrEP, those assigned to take 200 mg <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> within 72 hours of condomless sex had about one-third lower risk of STIs every three months compared with those who received no treatment (10 versus 32 percent, relative risk [RR] 0.34, 95% CI 0.24-0.46) [<a href="#rid66">66</a>]. With doxycycline, incidence of gonorrhea (RR 0.54, 95% CI 0.32-0.65), chlamydia (RR 0.12, 95% CI 0.05-0.25), and syphilis (RR 0.13, 95% CI 0.03-0.59) were all lower. Similar results were observed among an additional cohort of 174 MSM and transgender participants with HIV. The trial was stopped early for this observed effect. The results informed the adoption of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.sfcdcp.org%2Fwp-content%2Fuploads%2F2022%2F10%2FHealth-Update-Doxycycline-Post-Exposure-Prophylaxis-Reduces-Incidence-of-Sexually-Transmitted-Infections-SFDPH-FINAL-10.20.2022.pdf&amp;token=heMZ04%2BKT1mRGYM%2FTMF2k9jElmHVPsyMnoaZxiyhCBIZsBVjV5pxl3%2BAZ4l3tuJ1iDdKY7jiNT961iUhz5tIPug%2BZWcHMFd%2BQvPBeu%2FsnP45QxV%2Bllnye%2B6C0GTL%2F3ur3X%2Fe0%2FcOTvLvnJKEAVF%2F3PT2ZjOftF0CSB4Ex%2FKEKXJVZEaZQiQ3QIZYgmA3yK%2BJPpNu%2FoyLuNmGd0J3R%2BZ%2BDw%3D%3D&amp;TOPIC_ID=7595" target="_blank">local guidance in San Francisco</a> for doxycycline PEP among individuals disproportionately affected by STIs [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1">Similar findings were reported in abstract form only from a trial that included over 500 MSM on PrEP in France [<a href="#rid28">28</a>]. <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> PEP reduced the rates of syphilis (adjusted HR 0.21, 95% CI 0.09-0.47), chlamydia (adjusted HR 0.11, 95% CI 0.04-0.3), and gonorrhea (adjusted HR 0.49, 95% CI 0.032-0.76). Participants in this study were also randomly assigned to meningococcal conjugate vaccine or not, and no interaction with the doxycycline effect was identified. Doxycycline resistance in incident chlamydia was not detected among the PEP group. Publication of complete trial results is important to critically assess the findings.</p><p></p><p class="bulletIndent1">In contrast to the findings in cisgender men and transgender women, data do not suggest that <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> PEP is effective for cisgender women. A randomized trial of doxycycline PEP among 450 cisgender women in Kenya who were taking PrEP for HIV failed to demonstrate a reduction in incident bacterial STIs compared with no PEP (25 versus 29 cases per 100 person-years, RR 0.88; 95% CI 0.60-1.29) [<a href="#rid67">67</a>]. The reasons for the difference in effect between MSM and cisgender women are uncertain and undergoing further investigation. In the trial of cisgender women, testing for doxycycline levels in hair specimens suggested that adherence was likely suboptimal. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Gastrointestinal side effects of <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> were common in these studies; in one trial, 20 percent of participants discontinued STI PEP [<a href="#rid64">64</a>]. No serious adverse events were observed with doxycycline [<a href="#rid65">65</a>]. Long-term effects, including on individual- and population-level antimicrobial resistance rates, are uncertain but a potential concern. In one trial, doxycycline use was associated with a higher rate of <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> resistance in <em>N. gonorrhoeae</em> isolates, although the number of isolates evaluated for resistance was low (38 percent of 13 isolates from the doxycycline group versus 12 percent of 16 isolates from the standard care group and 27 percent of 15 isolates evaluated at baseline) [<a href="#rid66">66</a>]. Doxycycline use was also associated with a lower rate of <em>S. aureus</em> colonization (28 versus 47 percent) but a higher rate of resistance among those <em>S. aureus</em> isolates (16 versus 8 percent). A modelling study suggested that widespread adoption of PEP could lead to a substantial increase in doxycycline use at the population level, even accounting for reductions in need for bacterial STI treatment, and highlighted the importance of monitoring the uptake of the intervention, the resultant incidence of disease, and the impact on resistance [<a href="#rid68">68</a>].</p><p></p><p class="headingAnchor" id="H2005091246"><span class="h2">Presumptive treatment of bacterial STIs</span></p><p class="headingAnchor" id="H587191504"><span class="h3">For partners of patients diagnosed with syphilis, gonorrhea, chlamydia, or Trichomonas</span><span class="headingEndMark"> — </span>In the United States, the Centers for Disease Control and Prevention (CDC) recommends that sexual partners of patients diagnosed with syphilis, gonorrhea, chlamydia, or <em>Trichomonas</em> infection be presumptively treated for the pathogen that was identified in the index patient [<a href="#rid6">6</a>]. Partners unable or unwilling to be clinically evaluated can be treated for gonorrhea and/or chlamydia through the use of expedited partner therapy. (See <a class="local">'Partner services'</a> below.)</p><p class="headingAnchor" id="H3755762470"><span class="h3">For victims of sexual assault</span><span class="headingEndMark"> — </span>Pre-emptive empiric treatment of STIs is recommended in this setting, since many assault victims will not return for a follow-up visit, and treatment based upon microbiologic testing results is therefore problematic [<a href="#rid6">6</a>]. In addition, patients often prefer immediate treatment. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2765.html" rel="external">"Evaluation and management of adult and adolescent sexual assault victims in the emergency department"</a> and  <a class="medical medical_patient" href="/d/html/2721.html" rel="external">"Patient education: Care after sexual assault (Beyond the Basics)"</a>.)</p><p class="headingAnchor" id="H3281470"><span class="h2">Antiretroviral-based prevention of HIV</span><span class="headingEndMark"> — </span>Several effective strategies for HIV prevention employ the use of antiretroviral agents. </p><p>One of the most effective methods for prevention of HIV transmission is viral suppression of individuals with HIV. Effective antiretroviral treatment reduces HIV viral load in blood, semen, vaginal fluid, and rectal fluid to very low levels and reduces the risk of sexual HIV transmission by approximately 95 percent in HIV-serodiscordant couples [<a href="#rid69">69,70</a>]. Decreasing the community viral load by maximizing HIV diagnoses and effective linkage to effective HIV care can lead to dramatic reductions in HIV transmission [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/d/html/16612.html" rel="external">"HIV infection: Risk factors and prevention strategies", section on 'Treatment as prevention'</a>.)</p><p>For individuals without HIV who have high risk for HIV exposure and are committed to medication adherence and close follow-up, pre-exposure antiretroviral prophylaxis against HIV (HIV PrEP) is an effective strategy for prevention of HIV infection. This issue is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/113426.html" rel="external">"HIV pre-exposure prophylaxis"</a>.)</p><p>Although data are limited, observational studies have suggested a benefit of post-exposure antiretroviral prophylaxis (HIV PEP) in reducing the risk of HIV infection following sexual or other exposure to HIV [<a href="#rid72">72-77</a>]. This topic is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3768.html" rel="external">"Management of nonoccupational exposures to HIV and hepatitis B and C in adults"</a>.)</p><p class="headingAnchor" id="H24"><span class="h2">Suppressive therapy for herpes simplex virus</span><span class="headingEndMark"> — </span>Antiviral suppression of herpes simplex virus (HSV) is effective in decreasing the risk of transmission of HSV to an uninfected sex partner [<a href="#rid6">6</a>]. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/8346.html" rel="external">"Treatment of genital herpes simplex virus infection", section on 'Treatment options'</a>.)</p><p>Epidemiologic and biologic studies have suggested that genital HSV infection facilitates transmission and acquisition of HIV. However, antiviral suppression of HSV does not reduce the risk of HIV transmission from an HIV/HSV-coinfected individual nor does it reduce the risk of HIV acquisition in an individual with HSV. </p><p class="headingAnchor" id="H36"><span class="h2">Limited efficacy of topical microbicides</span><span class="headingEndMark"> — </span>Topical microbicides have been proposed as STI preventive agents by providing chemical, biologic, and physical barriers to infection at the mucosal surface (eg, vagina or rectum) [<a href="#rid78">78</a>]. Classes of microbicides include surfactants, membrane disruptors, favorable modifiers of the vaginal environment, viral entry inhibitors, and reverse transcriptase inhibitors [<a href="#rid79">79</a>]. Delivery systems include gel formulations and vaginal rings, which are engineered for sustained drug release [<a href="#rid80">80</a>].</p><p>However, clinical trials of microbicides (such as PRO2000) for the prevention of STIs such as gonorrhea, chlamydia, and syphilis have not demonstrated substantial efficacy [<a href="#rid81">81</a>]. </p><p>Studies of topical antiretroviral agents for the prevention of HIV acquisition are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/113426.html" rel="external">"HIV pre-exposure prophylaxis", section on 'Novel approaches to treatment'</a>.)</p><p class="headingAnchor" id="H44"><span class="h1">PARTNER SERVICES</span><span class="headingEndMark"> — </span>"Partner services" refers to actions by the provider or public health officials to identify and arrange for evaluation and treatment of sex partners of patients diagnosed with STIs [<a href="#rid6">6</a>]. From a public health standpoint, partner services can potentially decrease the spread of STIs and decrease the risk of reinfection of the index patient. The intensity of this effort varies among agencies and geographic areas. At the very least, clinicians should advise patients diagnosed with STIs to notify their partners and encourage them to be evaluated. In the United States, the Centers for Disease Control and Prevention (CDC) recommends that public health surveillance programs provide partner services for all persons who test positive for HIV and early syphilis and for those who are suspected to have cephalosporin-resistant gonorrhea [<a href="#rid6">6,82</a>].</p><p>Ideally, all sex partners of individuals diagnosed with any STI would receive clinical evaluation; however, there are circumstances when that is not possible. Expedited Partner Therapy (EPT) is the clinical practice of treating heterosexual sex partners of patients diagnosed with chlamydia or gonorrhea by providing medications or prescriptions to the patient to take to his/her partner without the health care provider first examining the partner. EPT has been shown to reduce reinfection of the index patient in several randomized clinical trials [<a href="#rid83">83-85</a>]. Both the CDC and the American College of Obstetricians and Gynecologists (ACOG) support the use of EPT as a method to prevent chlamydial and gonorrheal infection when a patient's partners are unable or unwilling to seek medical care [<a href="#rid86">86,87</a>]. EPT is legal or permissible in all but one state in the United States. EPT should be accompanied by patient counseling and written treatment instructions, with written encouragement to seek additional medical evaluation to screen for other STIs, including HIV. (See  <a class="medical medical_review" href="/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents", section on 'Management of sexual partners'</a> and  <a class="medical medical_review" href="/d/html/7579.html" rel="external">"Treatment of <i>Chlamydia trachomatis</i> infection", section on 'Expedited partner therapy'</a>.)</p><p>EPT is not recommended for men who have sex with men (MSM), in part because of the high risk of HIV and syphilis among these individuals [<a href="#rid88">88</a>]. It is recommended that they present for evaluation and treatment to minimize missed opportunities to diagnose these infections.</p><p class="headingAnchor" id="H3891585337"><span class="h1">OTHER PREVENTION MODALITIES</span></p><p class="headingAnchor" id="H757409080"><span class="h2">Male circumcision</span><span class="headingEndMark"> — </span>Numerous studies suggest a decreased risk of STI acquisition in males who have been circumcised; this is particularly evident for HIV infection [<a href="#rid89">89</a>]. </p><p>Nonsurgical circumcision measures appear to be safe and effective but have not yet been studied for their effect on HIV or STI prevention [<a href="#rid90">90</a>].</p><p class="headingAnchor" id="H522756214"><span class="h3">HIV infection</span><span class="headingEndMark"> — </span>The efficacy of male circumcision in preventing HIV acquisition among heterosexual men, women, and men who have sex with men is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/16612.html" rel="external">"HIV infection: Risk factors and prevention strategies", section on 'Male circumcision'</a>.)</p><p class="headingAnchor" id="H2579229833"><span class="h3">Other STIs</span><span class="headingEndMark"> — </span>Results of several studies suggest that male circumcision is associated with a reduced risk of viral STIs, including herpes simplex virus (HSV) type 2 and human papillomavirus (HPV), but not of gonorrhea or chlamydia [<a href="#rid91">91-94</a>]. As examples, several trials in Africa have suggested a relative reduction in HSV-2 seroconversion among men of approximately 25 to 40 percent following circumcision [<a href="#rid93">93-95</a>]. With regards to HPV infection, circumcision reduces acquisition and increases clearance of high-risk types among men and reduces HPV transmission to female sex partners by approximately 25 percent [<a href="#rid96">96-99</a>]. In contrast, circumcision did not reduce the risk of gonorrhea, chlamydia, or <em>Trichomonas </em>during two years of follow-up [<a href="#rid100">100,101</a>]. This variation may result from the site of infection, as gonorrhea and chlamydia infect the urethra, while viral infections tend to involve the foreskin, where dendritic cells play a prominent role.</p><p>An effect on the incidence of syphilis has also not been identified in these trials, possibly due to the low overall rate of syphilis in the study populations [<a href="#rid94">94</a>]. </p><p>The relationship between circumcision and chancroid or lymphogranuloma venereum (LGV) is unclear, but the best available data suggest a protective effect against chancroid [<a href="#rid102">102</a>] and possibly LGV [<a href="#rid103">103,104</a>]. A reduction in any infection associated with genital ulcers is important because the presence of these ulcers facilitates acquisition/transmission of HIV. </p><p>There is also evidence that urethral <em>Mycoplasma genitalium</em> infection is less prevalent in circumcised men [<a href="#rid105">105</a>].</p><p class="headingAnchor" id="H3392683486"><span class="h2">Outreach</span><span class="headingEndMark"> — </span>Outreach approaches to provide testing or preventive services to individuals disproportionally affected by STIs are frequently employed to engage populations who may not seek traditional facility-based health services [<a href="#rid106">106,107</a>]. With widespread use of the internet and mobile technology, these have emerged as avenues to reach individuals with preventive services [<a href="#rid108">108</a>]. As an example, increases in syphilis in the United States and Europe have been associated with meeting new and anonymous sex partners on the internet [<a href="#rid109">109-111</a>]. In response to this trend, some public health initiatives have created website-based prevention interventions and online syphilis-testing recruitment programs [<a href="#rid112">112,113</a>]. (See  <a class="medical medical_review" href="/d/html/7600.html" rel="external">"Syphilis in patients with HIV"</a>.)</p><p class="headingAnchor" id="H665067063"><span class="h2">Strategies to improve sexual health</span><span class="headingEndMark"> — </span>Some experts have argued that sexual health interventions in the United States are fragmented, leading to poor health outcomes (eg, STIs, teen pregnancy), decreased productivity among young adults, and overall higher health care costs. Such experts have suggested that a unified sexual health strategy should be developed to help decrease stigma, improve the delivery of care, enhance sex education, and ensure access to contraceptives [<a href="#rid114">114,115</a>]. </p><p class="headingAnchor" id="H805668460"><span class="h2">Anti-poverty measures</span><span class="headingEndMark"> — </span>Poverty has been shown to contribute to HIV and STI incidence among women [<a href="#rid116">116</a>]. A cluster-randomized trial in young women in Malawi suggests that anti-poverty measures and economic development can be important tools in STI prevention [<a href="#rid117">117,118</a>].</p><p class="headingAnchor" id="H919600684"><span class="h1">POLICY TO ENHANCE CLINICAL FOCUS ON SEXUAL HEALTH</span><span class="headingEndMark"> — </span>In the United States, several public health policy reports focusing on care and prevention of STIs have been issued or updated since 2018 [<a href="#rid119">119-122</a>]. In particular, the National Academies of Sciences, Engineering, and Medicine (NASEM) report, “Sexually Transmitted Infections: Adopting a Sexual Health Paradigm,” makes recommendations that are particularly relevant for health care providers [<a href="#rid122">122,123</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Adopt a sexual health paradigm – This entails incorporating a comprehensive sexual health assessment into routine care in most health care settings, as it is a necessary starting point for STI prevention and treatment. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Broaden ownership and accountability for responding to STIs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bolster existing systems and programs for responding to STIs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Embrace innovation and policy change to improve sexual health.</p><p></p><p>The report specifically endorses operationalizing and prioritizing sexual health promotion in practice guidelines and training curricula as well as incentivizing clinicians and nonclinical public health and social service professionals to make STI prevention and treatment dedicated practice areas. Programmatic priorities include having professional medical organizations develop clinical practice guidelines, recommendations, and benchmarks for the delivery of recommended sexual health services. It also recommends that licensing bodies for physicians, nurse practitioners, physician assistants, nurses, pharmacists, clinical social workers, and clinical psychologists require a minimum sexual health skillset, such as taking a comprehensive sexual assessment.</p><p class="headingAnchor" id="H1648711953"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111582.html" rel="external">"Society guideline links: Sexually transmitted infections"</a>.)</p><p class="headingAnchor" id="H27324087"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15379.html" rel="external">"Patient education: Chlamydia and gonorrhea (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/15442.html" rel="external">"Patient education: Genital herpes (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/132033.html" rel="external">"Patient education: Barrier methods of birth control (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/4015.html" rel="external">"Patient education: Chlamydia (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/4006.html" rel="external">"Patient education: Genital herpes (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H51"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessing sexual health and potential exposure to STI </strong>–<strong> </strong>Sexual health assessment through routine sexual histories is critical to allow targeted sexually transmitted infection (STI) screening and prevention counseling  (<a class="graphic graphic_table graphicRef61677" href="/d/graphic/61677.html" rel="external">table 2</a>). Factors associated with higher STI incidence include new or multiple sex partners, sex partners with recent STI, no or inconsistent condom use when having sex with multiple partners or with a partner who has multiple partners, trading sex for money or drugs, and sexual contact with sex workers. Adolescents, pregnant women, people with HIV, men who have sex with men (MSM), and transgender individuals warrant specific considerations for screening and counseling because of the high rate of STIs among these populations. (See <a class="local">'Sexual health assessment'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening for STIs</strong> – In addition to one-time screening for HIV infection in all adults and adolescents, all individuals being evaluated for STI screening or diagnosis should be tested for HIV infection. Screening for other STIs depends on the individual's sexual practices and demographic  (<a class="graphic graphic_table graphicRef103391" href="/d/graphic/103391.html" rel="external">table 1</a>). Screening for STIs is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7596.html" rel="external">"Screening for sexually transmitted infections"</a> and  <a class="medical medical_review" href="/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Counseling on prevention</strong> – Behavioral counseling interventions can reduce rates of STI in sexually active adolescents and adults who are disproportionately affected by STIs. They include in-person counseling, telephone support, and other media-delivered messages. Patient-centered counseling can be performed during a single brief session and entails assessing the patient's understanding of STI transmission, discussing the patient's sexual behavior, assessing the patient's willingness to change, negotiating a goal for behavioral change, and identifying a concrete and realistic step toward that goal  (<a class="graphic graphic_table graphicRef111349" href="/d/graphic/111349.html" rel="external">table 3</a>). (See <a class="local">'Prevention counseling'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccination</strong> – This is an important strategy to prevent several infections that are sexually transmitted or associated with sexual activity. Indications for relevant vaccines are discussed elsewhere. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8519" href="/d/drug information/8519.html" rel="external">Hepatitis A vaccine</a> (see  <a class="medical medical_review" href="/d/html/3900.html" rel="external">"Hepatitis A virus infection: Treatment and prevention", section on 'Indications'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hepatitis B vaccine (see  <a class="medical medical_review" href="/d/html/3641.html" rel="external">"Hepatitis B virus immunization in adults", section on 'Indications'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Human papillomavirus (HPV) vaccine (see  <a class="medical medical_review" href="/d/html/8325.html" rel="external">"Human papillomavirus vaccination"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Meningococcal vaccine (see  <a class="medical medical_review" href="/d/html/3901.html" rel="external">"Meningococcal vaccination in children and adults", section on 'Immunization of persons at increased risk'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mpox (formerly known as monkeypox) virus (see  <a class="medical medical_review" href="/d/html/8295.html" rel="external">"Treatment and prevention of mpox (monkeypox)", section on 'Orthopoxvirus vaccines'</a>)</p><p></p><p class="bulletIndent1">In addition to preventing meningococcal infection, meningococcal B vaccination has also been associated with reduced rates of gonorrhea. (See <a class="local">'Vaccines'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Barrier protection (condoms) </strong>–<strong> </strong>STI prevention efforts should also include the use of barrier methods, including male and female condoms. Use of male condoms has been associated with a decreased risk of transmission of HIV, chlamydia, gonorrhea, herpes simplex virus, and HPV. (See <a class="local">'Male condom use'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-exposure prophylaxis to prevent STI </strong>– Among MSM and transgender women who are disproportionately affected by STIs, a single dose of <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> PEP given within 24 to 72 hours of condomless sex can reduce the risk of syphilis, chlamydia, and gonorrhea. We individualize the decision to use doxycycline PEP given uncertainties around the long-term effect. (See <a class="local">'Doxycycline post-exposure prophylaxis for selected individuals'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other antimicrobial-based strategies</strong> – Effective preventive strategies include antiretroviral treatment as prevention, pre-exposure prophylaxis, and post-exposure prophylaxis to prevent HIV infection as well as suppressive antiviral therapy of individuals with genital herpes simplex virus (HSV) to prevent transmission. These issues are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/8344.html" rel="external">"Prevention of genital herpes virus infections", section on 'Chronic suppressive therapy in discordant couples'</a> and  <a class="medical medical_review" href="/d/html/16612.html" rel="external">"HIV infection: Risk factors and prevention strategies", section on 'Clinical approach to HIV prevention'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of sexual partners of individuals with STIs </strong>–<strong> </strong>Expedited partner therapy for sexual partners of patients diagnosed with gonorrhea or chlamydia who cannot be directly evaluated is an effective strategy to reduce STI reinfection rates. (See <a class="local">'Partner services'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effect of circumcision</strong> – Male circumcision can reduce HIV acquisition among heterosexual men. It has also been associated with a decreased risk of infection with HSV and HPV. (See <a class="local">'Male circumcision'</a> above and  <a class="medical medical_review" href="/d/html/16612.html" rel="external">"HIV infection: Risk factors and prevention strategies", section on 'Male circumcision'</a>.)</p><p></p><p class="headingAnchor" id="H1246383581"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Cynthia L Gay, MD, MPH, Myron S Cohen, MD, and Grace E Marx, MD, MPH, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Weström L. Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. Am J Obstet Gynecol 1980; 138:880.</a></li><li><a class="nounderline abstract_t">Goldenberg RL, Andrews WW, Yuan AC, et al. Sexually transmitted diseases and adverse outcomes of pregnancy. Clin Perinatol 1997; 24:23.</a></li><li><a class="nounderline abstract_t">Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2004; 2:33.</a></li><li><a class="nounderline abstract_t">Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992; 19:61.</a></li><li><a class="nounderline abstract_t">Røttingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis 2001; 28:579.</a></li><li><a class="nounderline abstract_t">Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.</a></li><li><a class="nounderline abstract_t">Ford JV, Ivankovich MB, Douglas JM Jr, et al. The Need to Promote Sexual Health in America: A New Vision for Public Health Action. Sex Transm Dis 2017; 44:579.</a></li><li><a class="nounderline abstract_t">Marcus JL, Snowden JM. Words Matter: Putting an End to "Unsafe" and "Risky" Sex. Sex Transm Dis 2020; 47:1.</a></li><li><a class="nounderline abstract_t">Mayer KH, de Vries H. HIV and sexually transmitted infections: responding to the "newest normal". J Int AIDS Soc 2018; 21:e25164.</a></li><li class="breakAll">National Academies of Sciences, Engineering, and Medicine. Sexually Transmitted Infections: Adopting a Sexual Health Paradigm, The National Academies Press, Washington, DC 2021.</li><li><a class="nounderline abstract_t">Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 2004; 36:6.</a></li><li class="breakAll">Centers for Disease Control and Prevention. High School YRBS. https://nccd.cdc.gov/youthonline/App/QuestionsOrLocations.aspx?CategoryId=C04 (Accessed on January 19, 2023).</li><li><a class="nounderline abstract_t">Kann L, McManus T, Harris WA, et al. Youth Risk Behavior Surveillance - United States, 2015. MMWR Surveill Summ 2016; 65:1.</a></li><li><a class="nounderline abstract_t">Kann L, McManus T, Harris WA, et al. Youth Risk Behavior Surveillance - United States, 2017. MMWR Surveill Summ 2018; 67:1.</a></li><li><a class="nounderline abstract_t">Crepaz N, Marks G, Liau A, et al. Prevalence of unprotected anal intercourse among HIV-diagnosed MSM in the United States: a meta-analysis. AIDS 2009; 23:1617.</a></li><li><a class="nounderline abstract_t">Johnson WD, Diaz RM, Flanders WD, et al. Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men. Cochrane Database Syst Rev 2008; :CD001230.</a></li><li><a class="nounderline abstract_t">Volk JE, Marcus JL, Phengrasamy T, et al. No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting. Clin Infect Dis 2015; 61:1601.</a></li><li class="breakAll">World Health Organization. Second meeting of the International Health Regulations (2005) (IHR) Emergency Committee regarding the multi-country outbreak of monkeypox. https://www.who.int/news/item/23-07-2022-second-meeting-of-the-international-health-regulations-(2005)-(ihr)-emergency-committee-regarding-the-multi-country-outbreak-of-monkeypox (Accessed on August 07, 2022).</li><li><a class="nounderline abstract_t">Allan-Blitz LT, Klausner JD. Current Evidence Demonstrates That Monkeypox Is a Sexually Transmitted Infection. Sex Transm Dis 2023; 50:63.</a></li><li><a class="nounderline abstract_t">Herbst JH, Jacobs ED, Finlayson TJ, et al. Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review. AIDS Behav 2008; 12:1.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2019. https://www.cdc.gov/std/statistics/2019/default.htm (Accessed on May 18, 2021).</li><li><a class="nounderline abstract_t">US Preventive Services Task Force, Krist AH, Davidson KW, et al. Behavioral Counseling Interventions to Prevent Sexually Transmitted Infections: US Preventive Services Task Force Recommendation Statement. JAMA 2020; 324:674.</a></li><li><a class="nounderline abstract_t">Dilley JW, Woods WJ, Loeb L, et al. Brief cognitive counseling with HIV testing to reduce sexual risk among men who have sex with men: results from a randomized controlled trial using paraprofessional counselors. J Acquir Immune Defic Syndr 2007; 44:569.</a></li><li class="breakAll">National Network of STD/HIV Prevention Training Center. Ask, Screen, Intervene Pocket Guide. http://nnptc.org/resources/ask-screen-intervene-pocket-guide/ (Accessed on December 16, 2016).</li><li><a class="nounderline abstract_t">Barrow RY, Ahmed F, Bolan GA, Workowski KA. Recommendations for Providing Quality Sexually Transmitted Diseases Clinical Services, 2020. MMWR Recomm Rep 2020; 68:1.</a></li><li><a class="nounderline abstract_t">Henderson JT, Senger CA, Henninger M, et al. Behavioral Counseling Interventions to Prevent Sexually Transmitted Infections: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2020; 324:682.</a></li><li><a class="nounderline abstract_t">Warner L, Klausner JD, Rietmeijer CA, et al. Effect of a brief video intervention on incident infection among patients attending sexually transmitted disease clinics. PLoS Med 2008; 5:e135.</a></li><li class="breakAll">Molina JM, Bercot B, Assoumou A, et al. ANRS 174 DOXYVAC: an open-label randomized trial to prevent STIs in MSM on PrEP. 30th CROI, Conference on Retroviruses and Opportunistic Infections, February 19-22, 2023, Seattle. Abstract 119.</li><li><a class="nounderline abstract_t">Petousis-Harris H, Paynter J, Morgan J, et al. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet 2017; 390:1603.</a></li><li><a class="nounderline abstract_t">Abara WE, Bernstein KT, Lewis FMT, et al. Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study. Lancet Infect Dis 2022; 22:1021.</a></li><li><a class="nounderline abstract_t">Wang B, Giles L, Andraweera P, et al. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study. Lancet Infect Dis 2022; 22:1011.</a></li><li><a class="nounderline abstract_t">Bruxvoort KJ, Lewnard JA, Chen LH, et al. Prevention of Neisseria gonorrhoeae With Meningococcal B Vaccine: A Matched Cohort Study in Southern California. Clin Infect Dis 2023; 76:e1341.</a></li><li><a class="nounderline abstract_t">Hook EW 3rd. An ounce of prevention. Ann Intern Med 2005; 143:751.</a></li><li class="breakAll">World Health Organization. Guidelines for the management of sexually transmitted infections. Geneva: World Health Organization 2003. www.who.int/reproductive-health/publications/rhr_01_10/0110.pdf (Accessed on November 15, 2011).</li><li><a class="nounderline abstract_t">Hariri S, Warner L. Condom use and human papillomavirus in men. J Infect Dis 2013; 208:367.</a></li><li class="breakAll">Workshop summary: scientific evidence on condom effectiveness for sexually transmitted diseases (STD) prevention. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Herndon, VA 2000.</li><li><a class="nounderline abstract_t">Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ 2004; 82:454.</a></li><li><a class="nounderline abstract_t">Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002; :CD003255.</a></li><li><a class="nounderline abstract_t">Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam Plann Perspect 1999; 31:272.</a></li><li><a class="nounderline abstract_t">Pinkerton SD, Abramson PR. Effectiveness of condoms in preventing HIV transmission. Soc Sci Med 1997; 44:1303.</a></li><li><a class="nounderline abstract_t">Warner L, Stone KM, Macaluso M, et al. Condom use and risk of gonorrhea and Chlamydia: a systematic review of design and measurement factors assessed in epidemiologic studies. Sex Transm Dis 2006; 33:36.</a></li><li><a class="nounderline abstract_t">Crosby RA, DiClemente RJ, Wingood GM, et al. Value of consistent condom use: a study of sexually transmitted disease prevention among African American adolescent females. Am J Public Health 2003; 93:901.</a></li><li><a class="nounderline abstract_t">Sánchez J, Campos PE, Courtois B, et al. Prevention of sexually transmitted diseases (STDs) in female sex workers: prospective evaluation of condom promotion and strengthened STD services. Sex Transm Dis 2003; 30:273.</a></li><li><a class="nounderline abstract_t">García PJ, Holmes KK, Cárcamo CP, et al. Prevention of sexually transmitted infections in urban communities (Peru PREVEN): a multicomponent community-randomised controlled trial. Lancet 2012; 379:1120.</a></li><li><a class="nounderline abstract_t">Ness RB, Randall H, Richter HE, et al. Condom use and the risk of recurrent pelvic inflammatory disease, chronic pelvic pain, or infertility following an episode of pelvic inflammatory disease. Am J Public Health 2004; 94:1327.</a></li><li><a class="nounderline abstract_t">Wald A, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001; 285:3100.</a></li><li><a class="nounderline abstract_t">Wald A, Langenberg AG, Krantz E, et al. The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med 2005; 143:707.</a></li><li><a class="nounderline abstract_t">Magaret AS, Mujugira A, Hughes JP, et al. Effect of Condom Use on Per-act HSV-2 Transmission Risk in HIV-1, HSV-2-discordant Couples. Clin Infect Dis 2016; 62:456.</a></li><li><a class="nounderline abstract_t">Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006; 354:2645.</a></li><li><a class="nounderline abstract_t">Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 2002; 29:725.</a></li><li><a class="nounderline abstract_t">Hogewoning CJ, Bleeker MC, van den Brule AJ, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer 2003; 107:811.</a></li><li><a class="nounderline abstract_t">Bleeker MC, Hogewoning CJ, Voorhorst FJ, et al. Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. Int J Cancer 2003; 107:804.</a></li><li><a class="nounderline abstract_t">Nielson CM, Harris RB, Nyitray AG, et al. Consistent condom use is associated with lower prevalence of human papillomavirus infection in men. J Infect Dis 2010; 202:445.</a></li><li><a class="nounderline abstract_t">Pierce Campbell CM, Lin HY, Fulp W, et al. Consistent condom use reduces the genital human papillomavirus burden among high-risk men: the HPV infection in men study. J Infect Dis 2013; 208:373.</a></li><li><a class="nounderline abstract_t">Repp KK, Nielson CM, Fu R, et al. Male human papillomavirus prevalence and association with condom use in Brazil, Mexico, and the United States. J Infect Dis 2012; 205:1287.</a></li><li><a class="nounderline abstract_t">Koss CA, Dunne EF, Warner L. A systematic review of epidemiologic studies assessing condom use and risk of syphilis. Sex Transm Dis 2009; 36:401.</a></li><li><a class="nounderline abstract_t">Wilkinson D, Tholandi M, Ramjee G, Rutherford GW. Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect Dis 2002; 2:613.</a></li><li><a class="nounderline abstract_t">Wetmore CM, Manhart LE, Wasserheit JN. Randomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future. Epidemiol Rev 2010; 32:121.</a></li><li><a class="nounderline abstract_t">Padian NS, van der Straten A, Ramjee G, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet 2007; 370:251.</a></li><li><a class="nounderline abstract_t">Ramjee G, van der Straten A, Chipato T, et al. The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial. PLoS One 2008; 3:e3488.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Doxycycline as STI PEP: Considerations for Individuals and Healthcare Providers of Gay or Bisexual Men or Transgender Women. https://www.cdc.gov/std/treatment-guidelines/clinical-primary.htm#CautionsForDoxyPEP (Accessed on January 19, 2023).</li><li class="breakAll">San Francisco Department of Public Health. Doxycycline PEP reduces incidence of STIs. October 20, 2022. https://www.sfcdcp.org/wp-content/uploads/2022/10/Health-Update-Doxycycline-Post-Exposure-Prophylaxis-Reduces-Incidence-of-Sexually-Transmitted-Infections-SFDPH-FINAL-10.20.2022.pdf (Accessed on March 02, 2023).</li><li><a class="nounderline abstract_t">Bolan RK, Beymer MR, Weiss RE, et al. Doxycycline prophylaxis to reduce incident syphilis among HIV-infected men who have sex with men who continue to engage in high-risk sex: a randomized, controlled pilot study. Sex Transm Dis 2015; 42:98.</a></li><li><a class="nounderline abstract_t">Molina JM, Charreau I, Chidiac C, et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis 2018; 18:308.</a></li><li class="breakAll">Luetkemyer A, Dombrowski J, Cohen S, et al. Doxycycline post-exposure prophylaxis for STI prevention among MSM and transgender women on HIV PrEP or living with HIV: high efficacy to reduce incident STI's in a randomized trial. Presented at Programme AIDS 2022. https://programme.aids2022.org/Abstract/Abstract/?abstractid=13231 (Accessed on January 19, 2023).</li><li><a class="nounderline abstract_t">Luetkemeyer AF, Donnell D, Dombrowski JC, et al. Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections. N Engl J Med 2023; 388:1296.</a></li><li><a class="nounderline abstract_t">Stewart J, Oware K, Donnell D, et al. Doxycycline Prophylaxis to Prevent Sexually Transmitted Infections in Women. N Engl J Med 2023; 389:2331.</a></li><li><a class="nounderline abstract_t">Roster KIO, Grad YH. Estimating changes in antibiotic consumption in the USA with the introduction of doxycycline post-exposure prophylaxis. Lancet Microbe 2024; 5:e9.</a></li><li><a class="nounderline abstract_t">Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493.</a></li><li><a class="nounderline abstract_t">Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med 2016; 375:830.</a></li><li><a class="nounderline abstract_t">Tanser F, Bärnighausen T, Grapsa E, et al. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 2013; 339:966.</a></li><li><a class="nounderline abstract_t">Schechter M, do Lago RF, Mendelsohn AB, et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr 2004; 35:519.</a></li><li><a class="nounderline abstract_t">Kahn JO, Martin JN, Roland ME, et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study. J Infect Dis 2001; 183:707.</a></li><li><a class="nounderline abstract_t">Heuker J, Sonder GJ, Stolte I, et al. High HIV incidence among MSM prescribed postexposure prophylaxis, 2000-2009: indications for ongoing sexual risk behaviour. AIDS 2012; 26:505.</a></li><li><a class="nounderline abstract_t">Mayer KH, Mimiaga MJ, Gelman M, Grasso C. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr 2012; 59:354.</a></li><li><a class="nounderline abstract_t">Sonder GJ, Prins JM, Regez RM, et al. Comparison of two HIV postexposure prophylaxis regimens among men who have sex with men in Amsterdam: adverse effects do not influence compliance. Sex Transm Dis 2010; 37:681.</a></li><li><a class="nounderline abstract_t">Diaz-Brito V, León A, Knobel H, et al. Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine. Antivir Ther 2012; 17:337.</a></li><li><a class="nounderline abstract_t">Pirrone V, Thakkar N, Jacobson JM, et al. Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob Agents Chemother 2011; 55:1831.</a></li><li><a class="nounderline abstract_t">Cutler B, Justman J. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis 2008; 8:685.</a></li><li><a class="nounderline abstract_t">Saxena BB, Han YA, Fu D, et al. Sustained release of microbicides by newly engineered vaginal rings. AIDS 2009; 23:917.</a></li><li><a class="nounderline abstract_t">Obiero J, Mwethera PG, Wiysonge CS. Topical microbicides for prevention of sexually transmitted infections. Cochrane Database Syst Rev 2012; :CD007961.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Recommendations for partner services programs for HIV infection, syphilis, gonorrhea, and chlamydial infection. MMWR Recomm Rep 2008; 57:1.</a></li><li><a class="nounderline abstract_t">Golden MR, Whittington WL, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005; 352:676.</a></li><li><a class="nounderline abstract_t">Schillinger JA, Kissinger P, Calvet H, et al. Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women: a randomized, controlled trial. Sex Transm Dis 2003; 30:49.</a></li><li><a class="nounderline abstract_t">Kissinger P, Mohammed H, Richardson-Alston G, et al. Patient-delivered partner treatment for male urethritis: a randomized, controlled trial. Clin Infect Dis 2005; 41:623.</a></li><li><a class="nounderline abstract_t">Committee opinion no 632: Expedited partner therapy in the management of gonorrhea and chlamydial infection. Obstet Gynecol 2015; 125:1526.</a></li><li class="breakAll">Centers for Disease Control &amp; Prevention (CDC). Expedited Partner Therapy. August 20, 2015. http://www.cdc.gov/std/ept/ (Accessed on July 10, 2016).</li><li><a class="nounderline abstract_t">Stekler J, Bachmann L, Brotman RM, et al. Concurrent sexually transmitted infections (STIs) in sex partners of patients with selected STIs: implications for patient-delivered partner therapy. Clin Infect Dis 2005; 40:787.</a></li><li><a class="nounderline abstract_t">Siegfried N, Muller M, Deeks J, et al. HIV and male circumcision--a systematic review with assessment of the quality of studies. Lancet Infect Dis 2005; 5:165.</a></li><li><a class="nounderline abstract_t">Mutabazi V, Kaplan SA, Rwamasirabo E, et al. HIV prevention: male circumcision comparison between a nonsurgical device to a surgical technique in resource-limited settings: a prospective, randomized, nonmasked trial. J Acquir Immune Defic Syndr 2012; 61:49.</a></li><li><a class="nounderline abstract_t">Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369:657.</a></li><li><a class="nounderline abstract_t">Wawer MJ, Makumbi F, Kigozi G, et al. Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet 2009; 374:229.</a></li><li><a class="nounderline abstract_t">Mahiane SG, Legeai C, Taljaard D, et al. Transmission probabilities of HIV and herpes simplex virus type 2, effect of male circumcision and interaction: a longitudinal study in a township of South Africa. AIDS 2009; 23:377.</a></li><li><a class="nounderline abstract_t">Tobian AA, Serwadda D, Quinn TC, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 2009; 360:1298.</a></li><li><a class="nounderline abstract_t">Tobian AA, Charvat B, Ssempijja V, et al. Factors associated with the prevalence and incidence of herpes simplex virus type 2 infection among men in Rakai, Uganda. J Infect Dis 2009; 199:945.</a></li><li><a class="nounderline abstract_t">Gray RH, Serwadda D, Kong X, et al. Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. J Infect Dis 2010; 201:1455.</a></li><li><a class="nounderline abstract_t">Serwadda D, Wawer MJ, Makumbi F, et al. Circumcision of HIV-infected men: effects on high-risk human papillomavirus infections in a randomized trial in Rakai, Uganda. J Infect Dis 2010; 201:1463.</a></li><li><a class="nounderline abstract_t">Senkomago V, Backes DM, Hudgens MG, et al. Acquisition and persistence of human papillomavirus 16 (HPV-16) and HPV-18 among men with high-HPV viral load infections in a circumcision trial in Kisumu, Kenya. J Infect Dis 2015; 211:811.</a></li><li><a class="nounderline abstract_t">Wawer MJ, Tobian AA, Kigozi G, et al. Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda. Lancet 2011; 377:209.</a></li><li><a class="nounderline abstract_t">Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369:643.</a></li><li><a class="nounderline abstract_t">Mehta SD, Moses S, Agot K, et al. Adult male circumcision does not reduce the risk of incident Neisseria gonorrhoeae, Chlamydia trachomatis, or Trichomonas vaginalis infection: results from a randomized, controlled trial in Kenya. J Infect Dis 2009; 200:370.</a></li><li><a class="nounderline abstract_t">Weiss HA, Thomas SL, Munabi SK, Hayes RJ. Male circumcision and risk of syphilis, chancroid, and genital herpes: a systematic review and meta-analysis. Sex Transm Infect 2006; 82:101.</a></li><li><a class="nounderline abstract_t">Van Howe RS. Genital ulcerative disease and sexually transmitted urethritis and circumcision: a meta-analysis. Int J STD AIDS 2007; 18:799.</a></li><li><a class="nounderline abstract_t">Langeni T. Male circumcision and sexually transmitted infections in Botswana. J Biosoc Sci 2005; 37:75.</a></li><li><a class="nounderline abstract_t">Mehta SD, Gaydos C, Maclean I, et al. The effect of medical male circumcision on urogenital Mycoplasma genitalium among men in Kisumu, Kenya. Sex Transm Dis 2012; 39:276.</a></li><li><a class="nounderline abstract_t">Ciesielski C, Kahn RH, Taylor M, et al. Control of syphilis outbreaks in men who have sex with men: the role of screening in nonmedical settings. Sex Transm Dis 2005; 32:S37.</a></li><li><a class="nounderline abstract_t">Denno DM, Chandra-Mouli V, Osman M. Reaching youth with out-of-facility HIV and reproductive health services: a systematic review. J Adolesc Health 2012; 51:106.</a></li><li><a class="nounderline abstract_t">Sullivan PS, Grey JA, Simon Rosser BR. Emerging technologies for HIV prevention for MSM: what we have learned, and ways forward. J Acquir Immune Defic Syndr 2013; 63 Suppl 1:S102.</a></li><li><a class="nounderline abstract_t">Taylor M, Aynalem G, Smith L, et al. Correlates of Internet use to meet sex partners among men who have sex with men diagnosed with early syphilis in Los Angeles County. Sex Transm Dis 2004; 31:552.</a></li><li><a class="nounderline abstract_t">McFarlane M, Bull SS, Rietmeijer CA. The Internet as a newly emerging risk environment for sexually transmitted diseases. JAMA 2000; 284:443.</a></li><li><a class="nounderline abstract_t">Elford J, Bolding G, Sherr L. Seeking sex on the Internet and sexual risk behaviour among gay men using London gyms. AIDS 2001; 15:1409.</a></li><li><a class="nounderline abstract_t">Klausner JD, Levine DK, Kent CK. Internet-based site-specific interventions for syphilis prevention among gay and bisexual men. AIDS Care 2004; 16:964.</a></li><li><a class="nounderline abstract_t">McFarlane M, Kachur R, Klausner JD, et al. Internet-based health promotion and disease control in the 8 cities: successes, barriers, and future plans. Sex Transm Dis 2005; 32:S60.</a></li><li><a class="nounderline abstract_t">Swartzendruber A, Zenilman JM. A national strategy to improve sexual health. JAMA 2010; 304:1005.</a></li><li><a class="nounderline abstract_t">Hogben M, Ford J, Becasen JS, Brown KF. A systematic review of sexual health interventions for adults: narrative evidence. J Sex Res 2015; 52:444.</a></li><li class="breakAll">Michael Harrington. The Other America: Poverty in the United States, Scribner, 1962.</li><li><a class="nounderline abstract_t">Baird SJ, Garfein RS, McIntosh CT, Ozler B. Effect of a cash transfer programme for schooling on prevalence of HIV and herpes simplex type 2 in Malawi: a cluster randomised trial. Lancet 2012; 379:1320.</a></li><li><a class="nounderline abstract_t">Pettifor A, McCoy SI, Padian N. Paying to prevent HIV infection in young women? Lancet 2012; 379:1280.</a></li><li class="breakAll">National Academy of Public Administration. The Impact of Sexually Transmitted Diseases on the United States: Still Hidden, Getting Worse, Can Be Controlled. https://napawash.org/uploads/NCSD_Final_Report_12.11.18.pdf (Accessed on January 07, 2022).</li><li class="breakAll">National Academy of Public Administration. STD Epidemic in America: The Front-line Struggle. https://www.ncsddc.org/wp-content/uploads/2019/11/NCSD-Phase-II-Final-Report.pdf (Accessed on January 07, 2022).</li><li class="breakAll">United States Department of Health and Human Services. STI National Strategic Plan. https://www.hhs.gov/sites/default/files/STI-National-Strategic-Plan-2021-2025.pdf (Accessed on January 07, 2022).</li><li class="breakAll">Sexually Transmitted Infections: Adopting a Sexual Health Paradigm, National Academies of Sciences, Engineering, and Medicine;Health and Medicine Division;Board on Population Health and Public Health Practice;Committee on Prevention and Control of Sexually Transmitted Infections in the United States. (Eds), National Academies Press (US), Washington (DC) 2021.</li><li><a class="nounderline abstract_t">Rietmeijer CA, Kissinger PJ, Guilamo-Ramos V, et al. Report From the National Academies of Sciences, Engineering and Medicine-STI: Adopting a Sexual Health Paradigm-A Synopsis for Sexually Transmitted Infection Practitioners, Clinicians, and Researchers. Sex Transm Dis 2022; 49:169.</a></li></ol></div><div id="topicVersionRevision">Topic 7595 Version 63.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7008604" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9099500" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Sexually transmitted diseases and adverse outcomes of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15035007" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The role of sexually transmitted diseases in HIV transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1595015" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11689757" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Sexually Transmitted Infections Treatment Guidelines, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28876308" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The Need to Promote Sexual Health in America: A New Vision for Public Health Action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31517770" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Words Matter: Putting an End to "Unsafe" and "Risky" Sex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29989338" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : HIV and sexually transmitted infections: responding to the "newest normal".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29989338" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : HIV and sexually transmitted infections: responding to the "newest normal".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14982671" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14982671" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27280474" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Youth Risk Behavior Surveillance - United States, 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29902162" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Youth Risk Behavior Surveillance - United States, 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19584704" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prevalence of unprotected anal intercourse among HIV-diagnosed MSM in the United States: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18646068" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26334052" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26334052" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36098576" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Current Evidence Demonstrates That Monkeypox Is a Sexually Transmitted Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17694429" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17694429" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32809008" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Behavioral Counseling Interventions to Prevent Sexually Transmitted Infections: US Preventive Services Task Force Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17310937" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Brief cognitive counseling with HIV testing to reduce sexual risk among men who have sex with men: results from a randomized controlled trial using paraprofessional counselors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17310937" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Brief cognitive counseling with HIV testing to reduce sexual risk among men who have sex with men: results from a randomized controlled trial using paraprofessional counselors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31899459" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Recommendations for Providing Quality Sexually Transmitted Diseases Clinical Services, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32809007" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Behavioral Counseling Interventions to Prevent Sexually Transmitted Infections: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18578564" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effect of a brief video intervention on incident infection among patients attending sexually transmitted disease clinics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18578564" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effect of a brief video intervention on incident infection among patients attending sexually transmitted disease clinics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28705462" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35427490" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35427492" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35642527" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prevention of Neisseria gonorrhoeae With Meningococcal B Vaccine: A Matched Cohort Study in Southern California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16287798" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : An ounce of prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16287798" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : An ounce of prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23644282" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Condom use and human papillomavirus in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23644282" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Condom use and human papillomavirus in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15356939" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effectiveness of condoms in preventing sexually transmitted infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11869658" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Condom effectiveness in reducing heterosexual HIV transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10614517" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The effectiveness of condoms in reducing heterosexual transmission of HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9141163" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effectiveness of condoms in preventing HIV transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16385221" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Condom use and risk of gonorrhea and Chlamydia: a systematic review of design and measurement factors assessed in epidemiologic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12773349" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Value of consistent condom use: a study of sexually transmitted disease prevention among African American adolescent females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12671544" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prevention of sexually transmitted diseases (STDs) in female sex workers: prospective evaluation of condom promotion and strengthened STD services.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22341824" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prevention of sexually transmitted infections in urban communities (Peru PREVEN): a multicomponent community-randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15284036" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Condom use and the risk of recurrent pelvic inflammatory disease, chronic pelvic pain, or infertility following an episode of pelvic inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11427138" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16287791" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The relationship between condom use and herpes simplex virus acquisition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26578538" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effect of Condom Use on Per-act HSV-2 Transmission Risk in HIV-1, HSV-2-discordant Couples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16790697" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Condom use and the risk of genital human papillomavirus infection in young women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12438912" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14566832" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14566831" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20569156" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Consistent condom use is associated with lower prevalence of human papillomavirus infection in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23644283" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Consistent condom use reduces the genital human papillomavirus burden among high-risk men: the HPV infection in men study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22396601" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Male human papillomavirus prevalence and association with condom use in Brazil, Mexico, and the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19455075" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A systematic review of epidemiologic studies assessing condom use and risk of syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12383611" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20519264" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Randomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17631387" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18941533" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18941533" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18941533" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25585069" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Doxycycline prophylaxis to reduce incident syphilis among HIV-infected men who have sex with men who continue to engage in high-risk sex: a randomized, controlled pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29229440" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29229440" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37018493" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38118022" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Doxycycline Prophylaxis to Prevent Sexually Transmitted Infections in Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37883986" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Estimating changes in antibiotic consumption in the USA with the introduction of doxycycline post-exposure prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21767103" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Prevention of HIV-1 infection with early antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27424812" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Antiretroviral Therapy for the Prevention of HIV-1 Transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23430656" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15021317" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11181146" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22156963" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : High HIV incidence among MSM prescribed postexposure prophylaxis, 2000-2009: indications for ongoing sexual risk behaviour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22267017" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20644499" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Comparison of two HIV postexposure prophylaxis regimens among men who have sex with men in Amsterdam: adverse effects do not influence compliance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22293542" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21343462" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Combinatorial approaches to the prevention and treatment of HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18992405" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Vaginal microbicides and the prevention of HIV transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19381077" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Sustained release of microbicides by newly engineered vaginal rings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22696373" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Topical microbicides for prevention of sexually transmitted infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18987617" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Recommendations for partner services programs for HIV infection, syphilis, gonorrhea, and chlamydial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15716561" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12514443" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16080084" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Patient-delivered partner treatment for male urethritis: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26000540" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Committee opinion no 632: Expedited partner therapy in the management of gonorrhea and chlamydial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26000540" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Committee opinion no 632: Expedited partner therapy in the management of gonorrhea and chlamydial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15736009" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Concurrent sexually transmitted infections (STIs) in sex partners of patients with selected STIs: implications for patient-delivered partner therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15766651" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : HIV and male circumcision--a systematic review with assessment of the quality of studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22739133" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : HIV prevention: male circumcision comparison between a nonsurgical device to a surgical technique in resource-limited settings: a prospective, randomized, nonmasked trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17321311" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19616720" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19198042" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Transmission probabilities of HIV and herpes simplex virus type 2, effect of male circumcision and interaction: a longitudinal study in a township of South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19321868" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Male circumcision for the prevention of HSV-2 and HPV infections and syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19220138" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Factors associated with the prevalence and incidence of herpes simplex virus type 2 infection among men in Rakai, Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20370483" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20370481" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Circumcision of HIV-infected men: effects on high-risk human papillomavirus infections in a randomized trial in Rakai, Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25261492" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Acquisition and persistence of human papillomavirus 16 (HPV-16) and HPV-18 among men with high-HPV viral load infections in a circumcision trial in Kisumu, Kenya.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21216000" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17321310" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19545209" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Adult male circumcision does not reduce the risk of incident Neisseria gonorrhoeae, Chlamydia trachomatis, or Trichomonas vaginalis infection: results from a randomized, controlled trial in Kenya.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16581731" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Male circumcision and risk of syphilis, chancroid, and genital herpes: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18073009" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Genital ulcerative disease and sexually transmitted urethritis and circumcision: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15688572" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Male circumcision and sexually transmitted infections in Botswana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22421693" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : The effect of medical male circumcision on urogenital Mycoplasma genitalium among men in Kisumu, Kenya.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16205290" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Control of syphilis outbreaks in men who have sex with men: the role of screening in nonmedical settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22824440" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Reaching youth with out-of-facility HIV and reproductive health services: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23673879" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Emerging technologies for HIV prevention for MSM: what we have learned, and ways forward.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15480117" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Correlates of Internet use to meet sex partners among men who have sex with men diagnosed with early syphilis in Los Angeles County.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10904506" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : The Internet as a newly emerging risk environment for sexually transmitted diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11504962" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Seeking sex on the Internet and sexual risk behaviour among gay men using London gyms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15511728" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Internet-based site-specific interventions for syphilis prevention among gay and bisexual men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16205295" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Internet-based health promotion and disease control in the 8 cities: successes, barriers, and future plans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20810379" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : A national strategy to improve sexual health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25406027" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : A systematic review of sexual health interventions for adults: narrative evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25406027" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : A systematic review of sexual health interventions for adults: narrative evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22341825" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Effect of a cash transfer programme for schooling on prevalence of HIV and herpes simplex type 2 in Malawi: a cluster randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22341826" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Paying to prevent HIV infection in young women?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22341826" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Paying to prevent HIV infection in young women?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22341826" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Paying to prevent HIV infection in young women?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22341826" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Paying to prevent HIV infection in young women?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22341826" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Paying to prevent HIV infection in young women?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34475355" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Report From the National Academies of Sciences, Engineering and Medicine-STI: Adopting a Sexual Health Paradigm-A Synopsis for Sexually Transmitted Infection Practitioners, Clinicians, and Researchers.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
